SCHEMBL2949958

SCHEMBL2949958

CCOC(=O)c1sc2c(ccc(=O)n2-c2ccccc2)c1Nc1cccnc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.44
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
ALDH1A1 P00352 3/20 0.44
MAPT P10636 5/20 0.43
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
HPGD P15428 1/20 0.42
NPEPPS P55786 2/20 0.42
POLB P06746 2/20 0.41
KDM4E B2RXH2 2/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
DHODH Q02127 1/20 0.40
TP53 P04637 1/20 0.40
FNTA P49354 1/20 0.40
FNTB P49356 1/20 0.40
GAA P10253 1/20 0.39
MDM2 Q00987 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1266606 0.90 MAPT (0.49) CSF1RMEN1KMT2AALDH1A1MAPT
SCHEMBL2952675 0.87 KMT2A (0.41) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL2953098 0.85 MAPT (0.46) CSF1RMEN1KMT2AALDH1A1MAPT
SCHEMBL2954053 0.84 DHODH (0.50) CSF1RMEN1KMT2AALDH1A1MAPT
SCHEMBL2958676 0.84 ALDH1A1 (0.47) CSF1RMEN1KMT2AALDH1A1MAPT
SCHEMBL2952196 0.83 MAPT (0.52) MEN1KMT2AALDH1A1MAPTNPC1
SCHEMBL5651778 0.83 MEN1 (0.48) MEN1KMT2AALDH1A1MAPTNPC1
SCHEMBL3837224 0.83 MAPT (0.51) MEN1KMT2AALDH1A1MAPTNPC1
SCHEMBL2955536 0.82 FNTA (0.44) CSF1RMEN1KMT2AALDH1A1MAPT
SCHEMBL2957153 0.82 MEN1 (0.46) CSF1RMEN1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7763729-B2 Bicyclic heteroaromatic derivatives UCB PHARMA S.A. (BE) 2010-07-27 US claimed
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives CELLTECH R&D LIMITED (GB) 2009-02-12 US claimed
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US claimed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US claimed
US-7763729-B2 Bicyclic heteroaromatic derivatives UCB PHARMA S.A. (BE) 2010-07-27 US disclosed
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives CELLTECH R&D LIMITED (GB) 2009-02-12 US disclosed
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US disclosed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors MAPK1, CNKSR1, ALK CSF1R 412/4885MEN1 4273/4885KMT2A 1316/4885
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives MAPK1, CNKSR1, CBR1 CSF1R 328/4885MEN1 3906/4885KMT2A 1383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.